ABEC, a provider of customised solutions and services for biopharmaceutical manufacturing, on Thursday announced the grand opening of its newest manufacturing facility in Wilson, North Carolina.
An official ribbon-cutting ceremony and facility opening celebration is planned for 24 September 2026, at 9:00am.
Located in one of the nation's fastest-growing life sciences regions, the new facility expands ABEC's global manufacturing network and is designed to strengthen the company's ability to support the rapidly growing biopharmaceutical industry with industry-leading equipment, consumables, and integrated process solutions.
The Wilson facility will manufacture bioprocess equipment and consumable products used in the development and production of biologics, vaccines, and other advanced medicines. The site complements ABEC's existing manufacturing operations in Bethlehem, Pennsylvania; Springfield, Missouri; Fermoy, Ireland; and Kells, Ireland.
Akeso presents positive results from registrational Phase III study of ivonescimab
US FDA grants orphan drug designation for Lundbeck's asedebart
ABL Diagnostics files bid to acquire IntegraGen
ABEC opens new manufacturing facility in Wilson, NC
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
Insilico Medicine doses first patient in Phase III trial of rentosertib
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer